HRA-19（人結(jié)腸癌腺癌細(xì)胞）
CBP60024
詢 價(jià)
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. General information | |
| Synonyms: | HRA-19 |
| Background: | The HRA-19 cell line was established from a primary human rectal adenocarcinoma present in a 66-year old male. The adenocarcinoma was well differentiated and determined to be Dukes' stage B. A clonal derivative of HRA-19 is available (HRA-19a1.1, ECACC catalogue number 09071517). HRA-19 has stem cell properties and undergoes a multilineage differentiation in serum free medium. A number of genetically modified derivatives of HRA-19 are also available. |
| Species: | human (Homo sapiens) |
| Tissue: | Rectum |
| Disease: | Human colorectal adenocarcinoma |
| Gender: | 66-year old male，UK |
| Morphology: | Epithelial |
| Growth Mode: | Adherent |
| Doubling Time: | N/A |
| DNA Profile: | Amelogenin: X,Y CSF1PO: 12 D13S317: 11,12 D16S539: 11 D5S818: 11 D7S820: 9,12 THO1: 8 TPOX: 11 vWA: 16 Our Cell Line Authentication Service |
| Culture Medium: |
DMEM+10%FBS We strongly suggest to purchase the complete medium from us. |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Karyotype: | Not specified |
| Subculture Routine: | Split sub-confluent cultures (70-80%) 1:5 to 1:10 weekly using 0.0125% trypsin/EDTA; 7.5% CO2; 37°C.Suggested seeding density 2-4x10,000 cells/cm². |
| Comments: | For more information, please contact us (4008-750-250). |
